Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Conditions
Interventions
Intervention1: NIL: THIS IS AN OBSERVATIONAL TRIAL
Control Intervention1: NIL: This is an observational study
Sponsors
Intramural funding Tata Memorial Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 5-39 years 2. Histological diagnosis of primary brain tumor 3. Decision for treatment with radical intent radiotherapy 4. Signed assent and parental consent form for pediatric age group and signed consent form for adults.
Exclusion criteria
Exclusion criteria: 1. Inability to undergo neurocognitive evaluation 2. Palliative radiotherapy. 3. Expected life expectancy less than 1 year
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Prediction of neurocognitive decline through identification of systemic biomarkers.Timepoint: The time point for sample collection (peripheral blood) would be before starting radiotherapy (Whenever available pre-operative blood samples will be collected). Along with this baseline sample, blood sample will also be collected weekly during the course of fractionated radiation (weekly for 6-7 weeks) and thereafter, 1 month after radiation completion and periodically at regular intervals (every 6-12 months) during follow-up visits. | — |
Primary
| Measure | Time frame |
|---|---|
| Biomarkers associated with radiation-induced neurocognitive declineTimepoint: The time point for sample collection (peripheral blood) would be before starting radiotherapy (Whenever available pre-operative blood samples will be collected). Along with this baseline sample, blood sample will also be collected weekly during the course of fractionated radiation (weekly for 6-7 weeks) and thereafter, 1 month after radiation completion and periodically at regular intervals (every 6-12 months) during follow-up visits. | — |
Countries
India
Contacts
Public ContactDr Kavita Pal
Advanced Centre for Treatment, Research and Education in Cancer(ACTREC),Tata Memorial centre
Outcome results
None listed